During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|December 10, 2012
FDA expands Zytiga's use for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
2
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
3
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
4
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
5